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A Homozygous Mutation in KCTD7 Links Neuronal Ceroid
Lipofuscinosis to the Ubiquitin-Proteasome System
John F. Staropoli,1,2 Amel Karaa,1 Elaine T. Lim,1,3 Andrew Kirby,1,3,4 Naser Elbalalesy,5
Stephen G. Romansky,6 Karen B. Leydiker,7 Scott H. Coppel,1 Rosemary Barone,1 Winnie Xin,1,8
Marcy E. MacDonald,1,8 Jose E. Abdenur,7 Mark J. Daly,1,3,4 Katherine B. Sims,1,8
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Neuronal ceroid lipofuscinosis (NCL) is a genetically heterogeneous group of lysosomal diseases that collectively compose the most
commonMendelian form of childhood-onset neurodegeneration. It is estimated that ~8% of individuals diagnosed with NCL by conser-
vative clinical and histopathologic criteria have been ruled out for mutations in the nine known NCL-associated genes, suggesting that
additional genes remain unidentified. To further understand the genetic underpinnings of the NCLs, we performed whole-exome
sequencing on DNA samples from a Mexican family affected by a molecularly undefined form of NCL characterized by infantile-onset
progressive myoclonic epilepsy (PME), vision loss, cognitive and motor regression, premature death, and prominent NCL-type storage
material. Using a recessive model to filter the identified variants, we found a single homozygous variant, c.550C>T in KCTD7, that
causes a p.Arg184Cys missense change in potassium channel tetramerization domain-containing protein 7 (KCTD7) in the affected
individuals. The mutation was predicted to be deleterious and was absent in over 6,000 controls. The identified variant altered the
localization pattern of KCTD7 and abrogated interaction with cullin-3, a ubiquitin-ligase component and known KCTD7 interactor.
Intriguingly, murine cerebellar cells derived from a juvenile NCL model (CLN3) showed enrichment of endogenous KCTD7. Whereas
KCTD7 mutations have previously been linked to PME without lysosomal storage, this study clearly demonstrates that KCTD7 muta-
tions also cause a rare, infantile-onset NCL subtype designated as CLN14.Neuronal ceroid lipofuscinosis (NCL) comprises a group
of at least nine distinct and currently untreatable lyso-
somal storage diseases with overlapping clinical features,
including progressive motor and cognitive decline,
pigmentary retinal degeneration and vision loss in most
cases, seizures, movement disorder, and eventual prema-
ture death.1 NCL is estimated to have a worldwide
prevalence of 1:100,000 individuals, and there is higher
prevalence in some geographic regions.1 Most forms of
NCL are autosomal recessive and show autofluorescent
lysosomal storage material with distinctive ultrastructural
morphology in many cell types. At least nine genes have
been implicated in the pathogenesis of NCL: PPT1 (CLN1
[MIM 600722]), TPP1 (CLN2 [MIM 607998]), CLN3 (MIM
607042), CLN5 (MIM 608102), CLN6 (MIM 606725),
MFSD8 (CLN7 [MIM 611124]), CLN8 (MIM 607837),
CTSD (CLN10 [MIM 116840]),2 and DNAJC5 (CLN4;
autosomal-dominant Kufs disease or late-onset NCL
[MIM 611203]).3,4 Despite the discovery of over 365
NCL-causing mutations in these genes, many clinically
suspected cases of NCL remain molecularly undefined,5
and these include ~8% of probands enrolled in the
Massachusetts General Hospital (MGH) NCL Registry.
With the aim of identifying novel causes of NCL, we
focused our efforts on samples from a family with more
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results of whole-exome sequencing and functional studies
to identify the gene defect in this family, in which
screening of the defined NCL-associated genes failed to
identify known or predicted deleterious variants.
Medical history from several individuals in a Mexican
family whose ancestors originated from the state of
Michoaca´n was reviewed, and DNA samples were obtained
after all subjects or legal guardians gave informed consent
as required by the institutional review board at MGH.
Both affected siblings (IV-1 and IV-2, Figure 2A) had
a normal birth and infancy and suffered from seizures
manifesting at 9 (IV-1) and 8 (IV-2) months of age. Seizure
manifestations, confirmed by electroencephalography and
video telemetry, included frequent myoclonic movements
involving mainly the face and extremities, were often
precipitated or worsened by fevers, and were refractory to
multiple antiepileptic drugs. Normal developmental mile-
stones were documented until the age of approximately
18 months, at which point motor and speech regression
were noted. By the ages of 12 years (IV-1) and 10 years
(IV-2), both siblings had microcephaly, were nonverbal,
and were without spontaneous motoric function. Both
IV-1 and IV-2 showed no response to visual threat and
had markedly diminished pupillary light reflexes; in
addition, IV-2 showedmild bilateral optic atrophy withoutton, MA 02114, USA; 2Department of Pathology, Massachusetts General
it, Department of Medicine, Massachusetts General Hospital, Boston, MA
A; 5Division of Neurology, Children’s Hospital of Orange County, Orange,
, CA 90806, USA; 7Division of Metabolic Disorders, Children’s Hospital of
usetts General Hospital, Boston, MA 02114, USA
y of Human Genetics. All rights reserved.
012
Figure 1. Storage Material in a Molecu-
larly Undefined Form of NCL
(A) Electron micrographs demonstrating
osmiophilic, membrane-bound storage
material from peripheral blood (left
panels) and a skin biopsy (right panels)
from the proband. Arrows point to lami-
nated inclusions, consistent with finger-
print profiles, in a lymphocyte. The upper
right panel shows a fibroblast distended
with a mixture of granular osmiophilic
deposits (asterisk) and filamentous mate-
rial, some of which is enclosed in vacuoles
(arrowheads). The lower right panel shows
a vacuole containing rectilinear profiles
within the axon of a myelinated nerve.
Scale bars represent 100 nm (lymphocyte),
500 nm (fibroblast), and 200 nm (nerve).
(B) Early-passage (p < 3) lymphoblastoid
cell lines were established from an affected
and unaffected sibling in the family
studied here, as well as from a JNCL subject
homozygous for a nonsense change
(p.Tyr199*) in CLN3 and from an unaffected sibling heterozygous for the same CLN3 change. Lysates (~30 mg) were probed for mito-
chondrial ATPase subunit c, the protein characteristically stored in NCL. GAPDH served as a loading control.apparent retinopathy. Brain imaging in both probands
showed global cortical atrophy, particularly marked in
the cerebellum, as well as thinning of the corpus callosum
and some loss of subcortical white matter in IV-1. Compre-
hensive metabolic testing of plasma, urine, and cerebro-
spinal fluid was normal in both siblings. A skin biopsy
performed on IV-2 for clinical diagnostic purposes at
11 years of age revealed prominent NCL-type storage
material in fibroblasts, neurons, and eccrine secretory
epithelial cells. Electron microscopy of a clinical buffy
coat sample from IV-2 was also remarkable for lysosomal
storage material containing fingerprint-like profiles and
granular osmiophilic deposits in ~15% of the analyzed
lymphocytes (Figure 1A). Moreover, immunoblot analysis
probing for subunit c of the mitochondrial ATP synthase,
the main stored proteolipid in most forms of NCL with
fingerprint, rectilinear, and curvilinear storage profiles,
revealed that the affected sibling had higher levels of
subunit c in a lymphoblastoid cell line than did the
unaffected sibling. This was similar to what was seen in
a lymphoblastoid cell line from a juvenile NCL (JNCL)
subject with a homozygous nonsense change in CLN3
(Figure 1B). Full sequencing of exons and flanking regions
for all known genes associated with autosomal-recessive
NCL (PPT1, TPP1, CLN3, CLN5, CLN6, MFSD8, CLN8,
and CTSD) identified no known or predicted pathogenic
mutations. Molecular analysis of genes associated with
seizure disorders (CDKL5, MECP2, SCN1A, SCN1B),
progressive myoclonic epilepsy (EPM2A, EPM2B, EFHC1,
CSTB, and dodecamer repeat expansion in CSTB), and
mitochondrial disease (including POLG1 mutations and
mutations associated with MELAS, MERRF, NARP, LHON,
KSS, and CPEO) were unrevealing. Peripheral-blood
lymphocytes from IV-2 were cytogenetically normal. Large
genomic deletions, duplications, and insertions were ruled
out on subjects IV-1 and IV-2 by array-based comparativeThe Amgenomic hybridization with an Agilent SurePrint G3
Human 4x180K microarray (MGH Diagnostic Molecular
Pathology Laboratory, Boston, MA). Both siblings died
from complications of progressive disease in their mid
teens but showed no apparent extra-CNS disease. A third
sibling in this family (IV-3) remains asymptomatic at age 7.
To identify a potential causative mutation in this family,
we performed whole-exome capture and sequencing by
using a NimbleGen SeqCap EZ Human Exome Library
v.2.0 (Otogenetics Corporation; Norcross, GA) on samples
from the two affected siblings (IV-1 and IV-2) and the
unaffected sibling (IV-3, Figure 2A). The average coverage
across each targeted exome was >503, and >95% of all
known SNPs were detected. The raw sequence data was
processed through the variant-calling pipeline at the Broad
Institute.6,7
Because the pattern of inheritance in this family was
most likely autosomal recessive, we screened the sequence
data for all pairs of homozygous and compound-heterozy-
gous nonsynonymous (i.e., nonsense, splice site, read-
through, missense, and indel) variants that were shared
in the two affected siblings (IV-1 and IV-2), but not in
the unaffected sibling (IV-3, Figure 2A). We required the
variants to be present at %0.1% minor allele frequency
in a set of 5,400 controls from the Exome Variant Server
(National Heart, Lung, and Blood Institute [NHLBI]
Exome Sequencing Project, Seattle, WA) given that the
frequency of the most common known NCL-associated
point and indel variants2 in this dataset is no greater
than 0.1% (data not shown). Only one such variant
fulfilled these criteria, and it mapped to exon 4 of
KCTD7, which is found in chromosomal region 7q11.21
and encodes potassium channel tetramerization domain-
containing protein 7 (isoform 1 [RefSeq accession number
NM_153033]; isoform 2 [RefSeq NM_001167961.2]).
This KCTD7 variant—c.550C>T leading to the predictederican Journal of Human Genetics 91, 202–208, July 13, 2012 203
Figure 2. A Private KCTD7 Variant Identified by Whole-Exome
Sequence Analysis of an Affected Sibling Pair and an Unaffected
Sibling
(A) A pedigree of the family shows similarly affected siblings (IV-1
and IV-2) that were ruled out for known forms of NCL by enzy-
matic and molecular testing. I-2 and I-3 are second cousins.
Although no known consanguinity existed between the parents
of the affected sibling pair, both sides of the family originate
from neighboring villages in the state of Michoaca´n, Mexico.
The green box indicates the sibling trio analyzed by whole-exome
sequencing.
(B) Sanger-sequence confirmation of the c.550C>T variant in
exon 4 of KCTD7.missense change p.Arg184Cys—was confirmed by Sanger
sequencing and was found to cosegregate in a recessive
pattern with the clinical phenotype; both affected siblings
were homozygous for the change, and the unaffected
sibling (IV-3), both parents (III-5, III-6), and paternal
grandmother (II-2) were heterozygous for the variant
(Figures 2A and 2B). The c.550C>T variant in KCTD7 was
also absent in another 822 control individuals from the
1000 Genomes Project;8 58 of these controls were of204 The American Journal of Human Genetics 91, 202–208, July 13, 2Mexican ancestry. Moreover, the p.Arg184Cys missense
change was predicted to be deleterious by HumVar-trained
PolyPhen-29 and SIFT10 and is found in a particularly
highly conserved region of KCTD7 (Figure S1, available
online).
Mutations in KCTD7 have previously been linked to
progressive myoclonic epilepsy (PME) in two families
(Table 1).11,12 Similar to the subjects we describe here,
affectedmembers of these families presented before 2 years
of age with myoclonic seizures primarily affecting the
face and extremities. All affected individuals showed
developmental regression, and their disease progressed to
death or severe disability by the first or second decade
of life. Given that PME is one of several seizure types
observed in NCL and given the strong evidence that the
p.Arg184Cys KCTD7 mutation is the causal variant in the
NCL-affected family studied here, we performed Sanger
sequencing of the KCTD7 coding region on an additional
set of 32 NCL samples (comprising both recessive and
dominant forms of NCL with heterogeneous seizure types)
that remain without molecular diagnosis. However, no
further KCTD7mutations were identified in this collection
of samples.
In the Van Bogaert et al. study, in which a homozygous
KCTD7 nonsense change (p.Arg99*) was found in three
PME subjects in a large consanguineous Moroccan family,
the ultrastructural analysis of skin biopsies from two of the
affected individuals was reported to be normal, implying
that there was no lysosomal storage in this family.11
Whether other PME subjects with KCTD7 mutations
were evaluated for lysosomal storage was not evident
(Table 1). Therefore, it is unclear whether KCTD7 muta-
tions produce allele-specific forms of PME, with or without
lysosomal storage, or whether these cases in fact represent
forms of NCL with false-negative peripheral biopsy results;
this latter scenario has been reported to be problematic in
the diagnosis of other forms of NCL.13 Of note, allele-
specific subphenotypes within the NCLs have also been
described. For example, the homozygous c.70C>G muta-
tion in CLN8 produces northern epilepsy (progressive
epilepsy with mental retardation), which is an early-onset
form of NCL without vision loss14 and is distinct from
variant late-infantile forms of CLN8 associated with vision
loss. Similarly, certain mutations in CLN6 cause adult-
onset forms of NCL without vision loss and appear to be
mutually exclusive with those that cause variant late-
infantile NCL with vision loss.15
KCTD7 bears an N-terminal bric a` brac, tramtrack, and
broad complex/poxvirus zinc finger (BTB/POZ) domain
that is homologous to the T1 tetramerization domain of
voltage-gated potassium channels16 and is shared with
several other functionally diverse members of the Kþ
channel tetramerization domain, or KCTD, protein
family.17–20 Little is known about the in vivo function of
KCTD7, but Kctd7 transcripts are highly expressed
throughout the murine brain, particularly in the mitral
cells of the olfactory bulb, hippocampus, cerebral cortex,012
Table 1. Clinicopathologic Comparison of Individuals with KCTD7 Mutations
Individuals with KCTD7 Mutations
IV-1 (This Study) IV-2 (This Study) Subject 111 Subject 211 Subject 311 Subject 412
Age of onset 9 months 8 months 18 months 24 months 16 months 10 months
Sex male female female female female male
Ethnicity Mexican Mexican Moroccan Moroccan Moroccan Turkish
KCTD7
mutation
c.550C>T
(p.Arg184Cys)
c.550C>T
(p.Arg184Cys)
c.295C>T
(p.Arg99*)
c.295C>T
(p.Arg99*)
c.295C>T
(p.Arg99*)
c.280C>T
(p.Arg94Trp)
Presenting
symptoms
myoclonus (face
and extremities)
and spasticity
myoclonus (face
and extremities)
precipitated
by fevers
myoclonus (face
and extremities)
tonic-clonic
seizures and
myoclonus
precipitated
by fevers
myoclonus
(extremities), head
shaking, sudden
loss of tone with
brief absences
myoclonic seizures,
tonic episodes,
hypotonia, dystonia,
and dyskinesia
Developmental
regression
yes yes yes yes yes yes
Eye findings vision loss (normal
retinal exam)
vision loss with
mild optic atrophy
NR NR normal vision NR
Brain imaging
(age)
cerebellar cortical
atrophy and thinning
of the corpus callosum
with loss of subcortical
white matter (12 years)
moderate generalized
brain atrophy more
pronounced in the
frontal lobes and
cerebellum (13 years)
NR NR normal
(19 months)
NR
Lysosomal
storage
ND NCL-type storage in
buffy coat and skin
absent NR absent NR
Disease course disease progression
and death at 13 years
disease progression,
status epilepticus, and
death at 17 years
disease progression
and wheel-chair
bound by 9 years
severe intellectual
disability,
microcephaly, and
seizure free on
medication
disease progression,
severe ataxia,
worsening seizures,
and death from
sepsis at 3 years
seizures resistant
to treatment
The following abbreviations are used: NR, not reported; ND, not determined; and NCL, neuronal ceroid lipofuscinosis.and Purkinje neurons of the cerebellum.21 Overexpression
of KCTD7 was reported to decrease the excitability of
cultured murine embryonic cortical neurons,21 but
whether this effect was mediated through potassium or
other ion channels was unclear.
To further investigate endogenous KCTD7 in the mouse,
we harvested multiple organs from a wild-type 5-month-
old C57BL/6J mouse, and we extracted proteins with
Tris-buffered saline containing 0.2% Triton X-100. Immu-
noblotting for KCTD7 with a rabbit polyclonal antibody
(ab83237 from Abcam [Cambridge, MA]) recognizing the
N-terminus of the protein revealed in whole-brain tissue
a high expression of a major ~31 kDa form that comigrated
with full-length KCTD7 that resulted from transient
KCTD7 overexpression in HEK 293T cells (Figure 3A).
Other major immunoreactive bands included a ~28 kDa
species, which was particularly prominent in the spleen,
liver, and kidneys, a ~37 kDa species most evident in the
kidneys, and a ~62 kDa form most likely corresponding
to an SDS-stable dimer, which we also observed in the
KCTD7-transiently-transfected HEK 293T cells, but not in
untransfected HEK 293T cells (Figure 3A and Figure S2A).
Evidence for KCTD7 homodimerization was also previ-
ously reported by Azizieh et al., who found that differently
tagged forms of KCTD7 in COS7 cells coimmunopre-
cipitated.21 The specificity of the bands was assessed byThe Amsecondary-only immunoblots, which yielded no bands
(data not shown), and by immunoblotting with two
additional commercially available KCTD7 antibodies,
which also labeled the above-described bands and gave
no signal when they were preincubated with the peptide
antigen (Figure S2). Here, the presence of multiple immu-
noreactive bands is consistent with evidence of alternative
splice variants21 and might indicate proteolytic cleavage
products. Therefore, despite the apparent ubiquitous
expression of KCTD7 as assessed by Northern blotting,21
these data strongly suggest tissue-specific differences in
KCTD7 regulation.
Given the high expression of Kctd7 in brain tissue,
including in cerebellar granule cells and Purkinje neurons
(Allen Brain Atlas), and the prominent cerebellar
pathology observed in patients, we assessed KCTD7 levels
and localization in conditionally immortalized murine
cerebellar granule cells, which have previously been
extensively used for cell biological studies of NCL.22 Of
the species detected on immunoblots of whole-tissue
homogenates, the ~28 kDa form was the most prominent.
Interestingly, all species, i.e., ~28 kDa, ~31 kDa, and
~62 kDa isoforms, were significantly elevated in cerebellar
granule cells derived from a murine JNCL model
(CbCln3Dex7/8/Dex7/8)21 (Figure 3A). This suggested an
impact of CLN3 loss of function on KCTD7 turnovererican Journal of Human Genetics 91, 202–208, July 13, 2012 205
Figure 3. KCTD7 Is Abundant in Brain
Tissue, and the NCL-Associated Variant
Alters Its Subcellular Localization and
Disrupts Its Interaction with Cullin-3
(A) The left panel shows protein lysates
that were isolated from the indicated
tissues from a wild-type 5-month-old
C57BL/6J mouse and then subjected
to SDS-PAGE and immunoblotting for
KCTD7. Approximately 100 mg of protein
were loaded per lane. Five micrograms of
protein lysate from HEK 293T cells trans-
fected with wild-type KCTD7 was loaded
as a reference. In the right panel, 30 mg of
protein from conditionally immortalized
CbCln3þ/þ or CbCln3 Dex7/8/Dex7/8 murine
cerebellar cell lysates was probed for
KCTD7 and GAPDH.
(B) Murine cerebellar cells (CbCln3þ/þ
cells) were transiently transfected with
GFP alone (not shown) or with constructs
encoding an N-terminal GFP fusion of
wild-type or p.Arg184Cys KCTD7, and
they were visualized by confocal micros-
copy. Arrows show sites of plasma-
membrane localization. The scale bar
represents 15 mm.
(C) HEK 293T cells were transiently trans-
fected with Myc-tagged cullin-3 (CUL3)
or cullin-1 (CUL1) and untagged wild-
type or p.Arg184Cys KCTD7. Lysates
were immunoprecipitated with the Myc
antibody and immunoblotted for KCTD7
or Myc. Lysates represent approximately
20% input. The asterisk indicates the
immunoglobulin light chain.because compared with Kctd7 expression in cells derived
from wild-type (CbCln3þ/þ) littermates,23 Kctd7 expres-
sion in CbCln3Dex7/8/Dex7/8 cerebellar cells was essentially
unchanged. Because immunohistochemistry did not suc-
cessfully detect KCTD7, we generated N-terminal green
fluorescent protein (GFP)-tagged forms of wild-type and
p.Arg184Cys KCTD7 by using Gateway Technology
(Invitrogen, Carlsbad, CA) and transiently transfected
cerebellar cells with the TransIt Express reagent (Mirus
Technologies, Madison, WI) (Figure 3B and Figures S2
and S3) in order to assess whether the identified mutation
affected expression and/or localization. Wild-type GFP-
KCTD7 showed broad, somewhat punctate cytoplasmic
localization and distinct signal at the plasma membrane.
In contrast, GFP-KCTD7 p.Arg184Cys showed more
diffuse cytoplasmic localization and markedly diminished
plasma-membrane signal, as well as prominent cyto-
plasmic aggregates (Figure 3B and Figure S3). All together,
these results suggest that the mutation affects the traf-
ficking and/or solubility of KCTD7. Expression of GFP
alone or of another fusion protein, GFP-LC3, a marker of
autophagosomes,24 did not produce similar aggregates
in cerebellar cells (data not shown and Cao et al.25). Addi-
tional localization studies in other neuronal subtypes, for
example, in primary neurons, will help further clarify the
impact of the p.Arg184Cys missense change on KCTD7
trafficking, turnover, and function.206 The American Journal of Human Genetics 91, 202–208, July 13, 2Similar to other members of the KCTD family,17,18
KCTD7 has been shown to interact with Cullin-3,21 a scaf-
folding component of several E3 ubiquitin-ligase com-
plexes that selectively tag proteins for degradation by the
proteasome.26 These interactions are mediated, at least
in part, through the BTB/POZ domain,17,18,27 but evidence
points to the role of critical residues outside this domain
as well.17,28,29 To determine whether the p.Arg184Cys
variant, which falls outside the BTB/POZ domain
(Figure S1), affects its interaction with Cullin-3, we tran-
siently cotransfected HEK 293T cells with constructs
encoding Myc-tagged Cullin-3 or Cullin-1 (another E3
ubiquitin-ligase protein component) and untagged wild-
type or p.Arg184Cys KCTD7, and we immunoprecipitated
lysates with a Myc antibody (clone 9E10, Origene, Rock-
land, MD). Cullin-3, but not Cullin-1, interacted robustly
with the SDS-stable dimeric form of wild-type KCTD7,
but the p.Arg184Cys missense change abrogated the
interaction with Cullin-3 (Figure 3C). The abrogated inter-
action between KCTD7 and Cullin-3 might lead to an
accumulation of substrate proteins, which might be toxic
and might lead to altered homeostasis of the ubiquitin-
proteasome system (UPS) and the other protein-degrada-
tion systems within the cell.
The identification of the KCTD7 mutation described in
this family establishes a rare, infantile-onset subtype of
NCL and indicates that KCTD7 should be considered in012
the diagnostic workup for molecularly undefined forms of
NCL in addition to PME.11,12 Moreover, further assessment
for evidence of lysosomal storage in PME subjects with
KCTD7mutations is warranted. In light of our recent find-
ings, we propose a designation of CLN14 for this form of
NCL; the synonymous CLN14 gene symbol for KCTD7
was approved by the Human Genome Organization
(HUGO) Gene Nomenclature Committee. The functional
effects of the causal variant in the current study are con-
sistent with the previously defined role of defective protein
processing in NCL25,30 and support a contribution from
the UPS. In particular, increasing evidence shows signifi-
cant crosstalk between autophagy and the UPS in a broad
range of neurodegenerative diseases.31,32 The activity of
cullin family members has specifically been linked to
endosomal33 and autophagosomal34,35 maturation, pro-
cesses that are defective in a murine model of JNCL.25
Therefore, determining the substrate(s) of the predicted
KCTD7- and Cullin-3-containing ubiquitin-ligase complex
and their potential role in NCL pathogenesis will be of
great interest in future studies.
Supplemental Data
Supplemental Data include three figures and can be found with
this article online at http://www.cell.com/AJHG.
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